Navigation Links
Repligen in Medical News

Repligen Licenses Patent Rights for Treatment of Bipolar Disorder

...WALTHAM, Mass., March 31 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...rogram of any private, U.S. psychiatric hospital. repligen is developing RG2417, an oral formulation of uridi... Herlihy, President and Chief Executive Officer of repligen Corporation. "Treatment of the symptoms of bipola...

Repligen Announces ISO 9001:2000 Certification

... WALTHAM, Mass., Feb. 12 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ), a global leader in ...lated services underlying its Protein A business. repligen has supplied Protein A products to the biopharmace...ent and Chief Executive Officer of Repligen. repligen is the world's leading supplier of recombinant Pro...

Repligen Reports Second Quarter Fiscal Year 2009 Financial Results

... WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported result... Herlihy, President and Chief Executive Officer of repligen Corporation. "As of September 30th, we had $65 mil...cologic, toxicologic and pharmacodynamic profiles. repligen announced receipt of a $1 million research grant f...

Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder

... WALTHAM, Mass., Nov. 6 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ...d relapse remain common clinical problems. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST

... WALTHAM, Mass., Oct. 30 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... be accessed at http://www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Compound Reverses Huntington's Symptoms in Mice

...published this week in the early edition of the Proceedings of the National Academy of Sciences . The study received funding from Massachusetts-based repligen Corp., which holds several patent applications related to HDAC (histone deacetylase) inhibitors, a class of agents that include HDACi 4b. Other HDA...

Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors

... WALTHAM, Mass., July 1 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "Fred's expertise and relationships w...es and is an inventor on numerous patents. About repligen Corporation ...

Repligen Announces Share Repurchase Program

... WALTHAM, Mass., June 18 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today announced that ...,000 shares of its common stock. Under the program repligen may repurchase shares from time to time at prevail... Herlihy, President and Chief Executive Officer of repligen Corporation. "Our strong financial position will a...

Repligen Announces Conference Call to Update Orencia(R) Lawsuit

... be accessed at http://www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...lings with the Securities and Exchange Commission. repligen assumes no obligation to update any forward-lookin...

Repligen Elects Earl Henry, M.D. to the Board of Directors

... WALTHAM, Mass., Dec. 13 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "Earl's strategic guidance and relati...rovider of clinical outsourcing solutions. About repligen Corporation ...
Repligen in Medical Technology

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

...Schimmel has also been the co-founder or founding director of numerous successful biotechnology companies, including Sirtris Pharmaceuticals, Alnylam, repligen Corporation, Alkermes, Inc., Momenta Pharmaceuticals and Cubist Pharmaceuticals, which were taken public on the NASDAQ and are well established as com...

Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer

...ing drugs to treat inherited and acquired energy impairment diseases. Dr. Rioux' three-decade career includes industry experience at companies such as repligen Corp., Arrow International, Variagenics, Inc., Biogen and GRP (Groupement de Recherche en Pharmacologie). He previously was a researcher in Clinical R...

Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder

... WALTHAM, Mass., June 12 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today announced that ...ill be the Principal Investigator of this study. repligen previously reported positive initial results from ...d over $200 million in funding since 1989. About repligen Corporation ...

Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging

...WALTHAM, Mass., April 16 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "We expect to complete patient enroll...s year and, if successful, file an NDA in 2009." repligen is currently conducting a Phase 3 clinical trial t...

Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging

...WALTHAM, Mass., March 26 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ... Herlihy, President and Chief Executive Officer of repligen Corporation. "There are approximately 150,000 panc...t could benefit from enhancement with secretin." repligen previously conducted a multi-center, baseline-cont...

Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder

... WALTHAM, Mass., Nov. 8 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today announced posit... Herlihy, President and Chief Executive Officer of repligen Corporation. "The results of this study support fu...ed over $200 million in funding since 1989. About repligen Corporation ...

Repligen Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas

... of Orphan Products Development of the FDA granted repligen orphan drug designation for RG1068, synthetic huma...of the pancreas. Orphan drug designation qualifies repligen for seven years of exclusive marketing rights in t...or RG1068 for MRI imaging of the pancreas. About repligen Corporation ...
Repligen in Biological Technology

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

... WALTHAM, Mass., Aug. 6 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported resul... Herlihy, President and Chief Executive Officer of repligen Corporation. "Our financial resources will allow ...ge in Bipolar Disorder scale (CGI-BP-C). In March, repligen exclusively licensed worldwide rights to a patent ...

Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results

... WALTHAM, Mass., July 30 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...e accessed at www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results

... WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported resul... Herlihy, President and Chief Executive Officer of repligen Corporation. "Over the next twelve months, we wil...DRS (p=0.01) and the CGI-BP-C (p=0.04). In March, repligen exclusively licensed worldwide rights to a patent ...

Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results

... WALTHAM, Mass., June 4 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that... be accessed at www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT

... WALTHAM, Mass., March 9 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...or 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Reports Third Quarter Fiscal Year 2009 Financial Results

... WALTHAM, Mass., Feb. 5 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) today reported resul... Herlihy, President and Chief Executive Officer of repligen Corporation. "Our financial resources will allow ...s. Stock Repurchase Program In June 2008, repligen announced that its Board of Directors authorized t...

Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST

... WALTHAM, Mass., Feb. 2 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...or 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results

... WALTHAM, Mass., Jan. 29 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that...ay be accessed at www.repligen.com . About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST

... WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ...ed for 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...

Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT

...WALTHAM, Mass., Sept. 17 /PRNewswire-FirstCall/ -- repligen Corporation (Nasdaq: RGEN ) announced today that ...ed for 30 days following the presentation. About repligen Corporation repligen Corporation is a biopharmaceutical company focused...
Repligen in Biological Dictionary

Affymetrix

...t news headlines at MainStreet.com Research AFFYMETRIX INC historical prices, historical volume, splits and dividends. ... Orexigen Therapeutics, repligen and Affymetrix lead small-cap volume in ... Affymetrix to Host Conference Call on July 22, 2009 to Announce Second Quarter 2009 Results ... Af...
Other Tags
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
(Date:7/9/2014)... Montefiore Medical Center and the Albert ... present new findings at the Alzheimer,s Association International Conference ... Copenhagen, Denmark. Data from the four abstracts will focus ... to mild cognitive impairment and dementia. The research is ... in 1980 to examine healthy brain aging as well ...
(Date:7/9/2014)... and have a reputation for being highly toxic, but when ... being being found to offer potential health benefits in a ... dementia. A new compound (AP39), designed and made at the ... by targeting delivery of very small amounts of the substance ... Scientists in Exeter have already found that the compound protects ...
(Date:7/9/2014)... study conducted by researchers at Tufts University School of ... intellectual and developmental disabilities, the likelihood of having cavities ... increased. The findings, published in the July/August issue of ... interventions designed to address the oral health of individuals ... dental records of 107 patients at one of the ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
Other Contents